Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | RECQL | P46063 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.48 |
| ▸ | BRAF | P15056 | 9/20 | 0.48 |
| ▸ | MAPK14 | Q16539 | 5/20 | 0.48 |
| ▸ | MAPK13 | O15264 | 2/20 | 0.47 |
| ▸ | KDR | P35968 | 2/20 | 0.47 |
| ▸ | TNNI3K | Q59H18 | 2/20 | 0.47 |
| ▸ | PTK2 | Q05397 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.45 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.44 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.44 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.44 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4300985 | 0.87 | KCNJ6 (0.50) | KDM4EBRAFMAPK14MAPK13KDR | |
| SCHEMBL2212728 | 0.82 | MAPK14 (0.72) | MEN1KMT2ABRAFMAPK14MAPK13 | |
| SCHEMBL2212924 | 0.75 | BRAF (0.62) | MEN1KMT2ABRAFMAPK14MAPK13 | |
| SCHEMBL2210314 | 0.75 | MAPK14 (0.62) | MEN1KMT2ABRAFMAPK14MAPK13 | |
| SCHEMBL2209824 | 0.75 | MAPK14 (0.62) | MEN1KMT2ABRAFMAPK14MAPK13 | |
| SCHEMBL3531298 | 0.74 | PTK2 (0.62) | KDM4EMEN1RECQLKMT2ACTDSP1 | |
| SCHEMBL3536896 | 0.74 | PTK2 (0.46) | KDM4EMEN1RECQLKMT2ACTDSP1 | |
| SCHEMBL3535452 | 0.74 | PTK2 (0.46) | KDM4EMEN1RECQLKMT2ACTDSP1 | |
| SCHEMBL13859627 | 0.74 | KCNJ6 (0.69) | BRAF | |
| SCHEMBL4307774 | 0.73 | MAPK13 (0.70) | BRAFMAPK14MAPK13PTK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090131437-A1 | DISUBSTITUTED UREAS AS KINASE INHIBITORS | CORIUM INTERNATIONAL, INC. (US) | 2009-05-21 | — | — | US | claimed |
| EP-1838700-A2 | DISUBSTITUTED UREAS AS KINASE INHIBITORS | Novartis AG (CH) | 2007-10-03 | — | — | EP | claimed |
| WO-2006072589-A2 | DISUBSTITUTED UREAS AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2006-07-13 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131437-A1 | DISUBSTITUTED UREAS AS KINASE INHIBITORS | UCK2, ULK2, MAP3K1 | KDM4E 834/4885MEN1 3254/4885RECQL 1634/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.